A Phase 3 interventional study of Placebo Inhalation Powder and Fluticasone Furoate/GW642444 Inhalation Powder in Asthma, sponsored by GlaxoSmithKline. Completed at 17 sites in 3 countries. Open to participants aged 12 Years to 65 Years. Per ClinicalTrials.gov, last updated 2017-01-18.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies testing fluticasone furoate in Asthma — none open to participants now, 3 under way, 2 of them phase 3. fluticasone furoate · Asthma.
Among the 40 studies testing fluticasone furoate in Asthma, this one is the 19th largest by enrollment, is one of 7 that started in 2010, is one of 14 in phase 3, and was the 11th registered.
4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.
Browse Asthma studies →None of the 40 studies testing fluticasone furoate in Asthma is open now. The open studies under Asthma, anywhere →
fluticasone furoate: first FDA approval 2007 (FLONASE SENSIMIST ALLERGY RELIEF), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.
This study: 12 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 7 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 185 is above the median of 79 across 3,344 interventional studies indexed under Asthma.
Median enrollment 102 across the 40 interventional studies. Of the 35 that completed or were terminated, 22 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
36 of 40 have an industry lead sponsor. The 4 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
262 studies in Asthma by GlaxoSmithKline: 7 open now, 12 under way, 7 of them phase 3. Of 240 finished, 132 (55%) have results posted.
Among the 262 studies in Asthma by GlaxoSmithKline, this one is the 95th largest by enrollment of the 238 interventional ones that give a count, is one of 34 that started in 2010, is one of 61 in phase 3, and was the 88th registered.
GlaxoSmithKline’s Asthma studies by the year they started, since 1999.
1 of the studies testing fluticasone furoate in Asthma that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05757102Phase 3GlaxoSmithKlineA Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma | 2027-01-26 |
Add it to your calendar (.ics) → With an account.
Among the 40 studies testing fluticasone furoate in Asthma, from their registry updates:
Among GlaxoSmithKline’s 262 in Asthma:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the effect of six weeks' treatment with two once-daily strengths of Fluticasone Furoate/GW642444 Inhalation Powder on the HPA axis system
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Fluticasone furoate/GW642444 Dose B inhalation powder once daily for 6 weeks' treatment + 1 oral placebo capsule each day on the last 7 days of the study
Drug: Fluticasone Furoate/GW642444 Inhalation Powder · Drug: Placebo Oral Capsule
Fluticasone furoate/GW642444 Dose A inhalation powder once daily for 6 weeks' treatment + 1 oral placebo capsule each day on the last 7 days of the study
Drug: Fluticasone Furoate/GW642444 Inhalation Powder · Drug: Placebo Oral Capsule
Placebo inhalation powder once daily for 6 weeks' treatment + 1 oral placebo capsule each day on the last 7 days of the study
Drug: Placebo Inhalation Powder · Drug: Placebo Oral Capsule
Placebo inhalation powder once daily for 6 weeks' treatment + 1 oral prednisolone 10mg capsule each day on the last 7 days of the study
Drug: Placebo Inhalation Powder · Drug: Prednisolone Oral Capsule
Placebo Inhalation powder inhaled once daily for 6 weeks' treatment
Drug pages: Fluticasone furoate · Vilanterol
Dose B inhaled once daily for 6 weeks' treatment
Drug pages: Fluticasone furoate · Vilanterol
Dose A inhaled once daily for 6 weeks' treatment
One placebo capsule taken each day on the last 7 days of the study
Prednisolone 10mg oral capsule taken each day on the last 7 days of the study
Ratio From Baseline of the Serum Cortisol Weighted Mean (0-24 Hours) on Day -1/1 (Baseline) and Day 42
Serum cortisol weighted mean was determined for each participant over the time period 0-12 hours on Day -1/1 (Baseline) and Day 42. Serum cortisol weighted mean was derived by dividing the area under the concentration-time curve (AUC; defined as thearea under the concentration-time curve from time zero up to 24 hours) by the sample collection time interval. The sample collection time interval is defined as the difference between the time of the last cortisol sample and the time of the first cortisol sample. Samples were collected at the following time points: 0 (first blood draw/pre-dose); 2, 4, 9, 12, 14, 16, 20, 22, and 24 hours (relative to the "0" time point). Because values are on a logged scale, the ratio of the endpoint to Baseline is presented, as it is a measure of the difference from Baseline.
Time frame: Day -1/1 (Baseline) and Day 42
Ratio From Baseline of the Serum Cortisol Area Under the Concentration-time Curve (AUC) (0-24 Hour) on Day -1/1 (Baseline) and Day 42
Area under the plasma drug concentration-time (AUC\[0-24 hour\]) curve from time zero (pre-dose) to the last time of quantifiable serum cortisol concentration at 24 hours post-dose on Day -1/1 (Baseline) and Day 42 was measured. AUC reflects the actual body exposure to drug over a specified period of time after administration of a dose. Samples were collected at the following times: 0 (immediately pre-dose inhaled study drug); post-dose at 5 minutes (min), 15 min, 30 min, and 1 hour (hr), 2 hr, 4 hr, 9 hr, 12 hr, 16 hr, 20 hr, and 24 hr. Because values are on a logged scale, the ratio of the endpoint to Baseline is presented, as it is a measure of the difference from Baseline.
Time frame: Day -1/1 (Baseline) and Day 42
Ratio From Baseline of Serum Cortisol Trough (0-24 Hours) at Day -1/1 (Baseline) and Day 42
Serum cortisol trough is defined as the minimum value of serum cortisol measured over the 24-hour period. Samples were collected at the following times: 0 (immediately pre-dose inhaled study drug); post-dose at 5 minutes (min), 15 min, 30 min, and 1 hour (hr), 2 hr, 4 hr, 9 hr, 12 hr, 16 hr, 20 hr, and 24 hr. Because values are on a logged scale, the ratio of the endpoint to Baseline is presented, as it is a measure of the difference from Baseline.
Time frame: Day -1/1 (Baseline) and Day 42
Ratio From Baseline of 0-24 Hour Urinary Free Cortisol Excretion on Day -1/1 (Baseline) and Day 42
A 24-hour urine sample was collected for the measurement of 24-hour urinary cortisol excretion at Day -1/1 (Baseline) and Day 42. Only those participants available at the specified time points were analyzed. Because values are on a logged scale, the ratio of the endpoint to Baseline is presented, as it is a measure of the difference from Baseline.
Time frame: Day -1/1 (Baseline) and Day 42
Plasma FF and VI Pharmacokinetic (PK) Concentration
Plasma FF and VI Pharmacokinetic (PK) Concentration were estimates at the following time points:0 (immediately pre-dose inhaled study drug), and post-dose at 5 min, 15 min, 30 min, and 1 hr, 2 hr, 4 hr, 9 hr, 12 hr, 16 hr, 20 hr, 24 hr on Day 42. Only those participants available at the specified time points were analyzed (represented by n=X, X, X, X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the Pharmacokinetic Population.
Time frame: Day 42
AUC(0-t) and AUC(0-24) for FF on Day 42
Area under the plasma drug concentration-time (AUC\[0-t\]) curve from time zero (pre-dose) to the last time of quantifiable FF concentration and AUC(0-24) is the concentration time curve from zero (pre-dose) to 24 hours of quantifiable FF concentration on Day 42 was measured. AUC reflects the actual body exposure to drug over a specified period of time after administration of a dose. Samples were collected at the following times: 0 (immediately pre-dose inhaled study drug); post-dose at 5 minutes (min), 15 min, 30 min, and 1 hour (hr), 2 hr, 4 hr, 9 hr, 12 hr, 16 hr, 20 hr, and 24 hr post-dose on Day 42.
Time frame: Day 42
Cmax for FF on Day 42
Cmax is defined as the maximum observed concentration on Day 42. Samples were collected at the following times: 0 (immediately pre-dose inhaled study drug); post-dose at 5 minutes (min), 15 min, 30 min, and 1 hour (hr), 2 hr, 4 hr, 9 hr, 12 hr, 16 hr, 20 hr, and 24 hr post-dose on Day 42.
Time frame: Day 42
Tmax and Tlast of FF at Day 42
tmax is defined as the time to reach the observed maximum concentration, and tlast is defined as the time of the last observed quantifiable concentration on Day 42. Samples were collected at the following times: 0 (immediately pre-dose inhaled study drug); post-dose at 5 minutes (min), 15 min, 30 min, and 1hour (hr), 2 hr, 4 hr, 9 hr, 12 hr, 16 hr, 20 hr, and 24 hr post-dose on Day 42.
Time frame: Day 42
AUC(0-t) for VI on Day 42
Area under the concentration-time (AUC\[0-t\]) curve from time zero (pre-dose) to the last time of quantifiable VI concentration on Day 42 was measured. Samples were collected at the following times: 0 (immediately pre-dose inhaled study drug); post-dose at 5 minutes (min), 15 min, 30 min, and 1 hour (hr), 2 hr, 4 hr, 9 hr, 12 hr, 16 hr, 20 hr, and 24 hr post-dose on Day 42.
Time frame: Day 42
Cmax for VI on Day 42
Cmax is defined as the maximum observed concentration on Day 42. Samples were collected at the following times: 0 (immediately pre-dose inhaled study drug); post-dose at 5 minutes (min), 15 min, 30 min, and 1 hour (hr), 2 hr, 4 hr, 9 hr, 12 hr, 16 hr, 20 hr, and 24 hr post-dose on Day 42.
Time frame: Day 42
Tmax and Tlast of VI at Day 42
tmax is defined as the time to reach the observed maximum concentration, and tlast is defined as the time of the last observed quantifiable VI concentration on Day 42. Samples were collected at the following times: 0 (immediately pre-dose inhaled study drug); post-dose at 5 minutes (min), 15 min, 30 min, and 1hour (hr), 2 hr, 4 hr, 9 hr, 12 hr, 16 hr, 20 hr, and 24 hr post-dose on Day 42.
Time frame: Day 42
Number of Participants With Any Adverse Event (AE) or Any Serious Adverse Event (SAE) During the Treatment Period
An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A serious adverse event (SAE) is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect. Medical or scientific judgment should be exercised in deciding whether reporting is appropriate in other situations. Refer to the General Adverse AE/SAE module for a complete list of AEs and SAEs.
Time frame: From the start of study medication until Day 42 (Visit 5)/Early Withdrawal
Change From Baseline in Basophil, Eosinophil, Lymphocyte, Monocyte, and Segmented Neutrophil Values at Day 42/Early Withdrawal (EW)
Blood samples were collected for the measurement of basophils, eosinophils, lymphocytes, monocytes, and segmented neutrophils at Baseline and Day 42/EW. For all laboratory assessments, Baseline is the most recent recorded value at Screening or prior to Day -1/1. Change from Baseline was calculated as the Day 42/EW value minus the Baseline value.
Time frame: Baseline and Day 42/Early Withdrawal (EW)
Change From Baseline in Eosinophil, Total Neutrophil, Platelet, and White Blood Cell (WBC) Count Values at Day 42/EW
Blood samples were collected for the measurement of eosinophils, total neutrophils, platelets, and WBC count at Baseline and Day 42/EW. For all laboratory assessments, Baseline is the most recent recorded value at Screening or prior to Day -1/1. Change from Baseline was calculated as the Day 42/EW value minus the Baseline value.
Time frame: Baseline and Day 42/EW
Change From Baseline in Hemoglobin Values at Day 42/EW
Blood samples were collected for the measurement of hemoglobin at Baseline and Day 42/EW. For all laboratory assessments, Baseline is the most recent recorded value at Screening or prior to Day -1/1. Change from Baseline was calculated as the Day 42/EW value minus the Baseline value.
Time frame: Baseline and Day 42/EW
Change From Baseline in Hematocrit Values at Day 42/EW
Blood samples were collected for the measurement of hematocrit at Baseline and Day 42/EW. For all laboratory assessments, Baseline is the most recent recorded value at Screening or prior to Day -1/1. Change from Baseline was calculated as the Day 42/EW value minus the Baseline value.
Time frame: Baseline and Day 42/EW
Change From Baseline in Alanine Amino Transferase (ALT), Alkaline Phosphatase (ALP), Aspartate Amino Transferase (AST), Creatine Kinase (CK), and Gamma Glutamyl Transferase (GGT) Values at Day 42/EW
Blood samples were collected for the measurement of ALT, ALP, AST, CK, and GGT at Baseline and Day 42/EW. For all laboratory assessments, Baseline is the most recent recorded value at Screening or prior to Day -1/1. Change from Baseline was calculated as the Day 42/EW value minus the Baseline value.
Time frame: Baseline and Day 42/EW
Change From Baseline in Albumin and Total Protein Values at Day 42/EW
Blood samples were collected for the measurement of albumin and total protein at Baseline and Day 42/EW. For all laboratory assessments, Baseline is the most recent recorded value at Screening or prior to Day -1/1. Change from Baseline was calculated as the Day 42/EW value minus the Baseline value.
Time frame: Baseline and Day 42/EW
Change From Baseline in Direct Bilirubin, Indirect Bilirubin, Total Bilirubin, and Creatinine Values at Day 42/EW
Blood samples were collected for the measurement of direct bilirubin, indirect bilirubin, total bilirubin, and creatinine at Baseline and Day 42/EW. For all laboratory assessments, Baseline is the most recent recorded value at Screening or prior to Day -1/1. Change from Baseline was calculated as the Day 42/EW value minus the Baseline value.
Time frame: Baseline and Day 42/EW
Change From Baseline in Chloride, Carbon Dioxide (CO2) Content/Bicarbonate, Glucose, Potassium, Sodium, and Urea/Blood Urea Nitrogen (BUN) Values at Day 42/EW
Blood samples were collected for the measurement of chloride, carbon dioxide (CO2) content/bicarbonate, glucose, potassium, sodium, and urea/blood urea nitrogen (BUN) at Baseline and Day 42/EW. For all laboratory assessments, Baseline is the most recent recorded value at Screening or prior to Day -1/1. Change from Baseline was calculated as the Day 42/EW value minus the Baseline value.
Time frame: Baseline and Day 42/EW
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at Days 14, 28, 42, and Maximum Post-Baseline
SBP and DBP were measured at Baseline and at Days 14, 28, 42, and EW. Change from Baseline was calculated as the Day 42/EW value minus the Baseline value. Scheduled, unscheduled, and early withdrawal visits were used for the maximum post-Baseline assessment.
Time frame: Days 14, 28, 42, and EW
Change From Baseline in Pulse Rate at Days 14, 28, 42, and Maximum Post-Baseline
Heart rate was measured at Baseline and at Days 14, 28, 42, and EW. Change from Baseline was calculated as the Day 42/EW value minus the Baseline value. Scheduled, unscheduled, and early withdrawal visits were used for the maximum post-Baseline assessment.
Time frame: Days 14, 28, 42, and EW
Participants who met all the inclusion criteria entered a 7- to 14-day Run-in Period (screening visit \[Visit 1\]). Participants were provided with albuterol/salbutamol inhalation aerosol for relief of asthma symptoms during the study.
| Milestone | Placebo | FF/VI 100/25 µg PM | FF/VI 200/25 µg PM | Prednisolone 10 mg AM |
|---|---|---|---|---|
| Started | 58 | 56 | 56 | 15 |
| Completed | 55 | 54 | 55 | 13 |
| Not completed | 3 | 2 | 1 | 2 |
| Withdrew: Adverse event | 1 | 0 | 0 | 2 |
| Withdrew: Lack of efficacy | 1 | 1 | 0 | 0 |
| Withdrew: Protocol violation | 1 | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 0 |
Serum cortisol weighted mean was determined for each participant over the time period 0-12 hours on Day -1/1 (Baseline) and Day 42. Serum cortisol weighted mean was derived by dividing the area under the concentration-time curve (AUC; defined as thearea under the concentration-time curve from time zero up to 24 hours) by the sample collection time interval. The sample collection time interval is defined as the difference between the time of the last cortisol sample and the time of the first cortisol sample. Samples were collected at the following time points: 0 (first blood draw/pre-dose); 2, 4, 9, 12, 14, 16, 20, 22, and 24 hours (relative to the "0" time point). Because values are on a logged scale, the ratio of the endpoint to Baseline is presented, as it is a measure of the difference from Baseline.
| ratio from Baseline | Placebo | FF/VI 100/25 µg PM | FF/VI 200/25 µg PM | Prednisolone 10 mg AM |
|---|---|---|---|---|
| Ratio From Baseline of the Serum Cortisol Weighted Mean (0-24 Hours) on Day -1/1 (Baseline) and Day 42 | 0.99 ± 29.6 | 0.99 ± 40.0 | 0.96 ± 27.2 | 0.32 ± 72.9 |
Area under the plasma drug concentration-time (AUC\[0-24 hour\]) curve from time zero (pre-dose) to the last time of quantifiable serum cortisol concentration at 24 hours post-dose on Day -1/1 (Baseline) and Day 42 was measured. AUC reflects the actual body exposure to drug over a specified period of time after administration of a dose. Samples were collected at the following times: 0 (immediately pre-dose inhaled study drug); post-dose at 5 minutes (min), 15 min, 30 min, and 1 hour (hr), 2 hr, 4 hr, 9 hr, 12 hr, 16 hr, 20 hr, and 24 hr. Because values are on a logged scale, the ratio of the endpoint to Baseline is presented, as it is a measure of the difference from Baseline.
| ratio from Baseline | Placebo | FF/VI 100/25 µg PM | FF/VI 200/25 µg PM | Prednisolone 10 mg AM |
|---|---|---|---|---|
| Ratio From Baseline of the Serum Cortisol Area Under the Concentration-time Curve (AUC) (0-24 Hour) on Day -1/1 (Baseline) and Day 42 | 0.99 ± 29.6 | 0.99 ± 40.1 | 0.97 ± 27.2 | 0.32 ± 71.9 |
Serum cortisol trough is defined as the minimum value of serum cortisol measured over the 24-hour period. Samples were collected at the following times: 0 (immediately pre-dose inhaled study drug); post-dose at 5 minutes (min), 15 min, 30 min, and 1 hour (hr), 2 hr, 4 hr, 9 hr, 12 hr, 16 hr, 20 hr, and 24 hr. Because values are on a logged scale, the ratio of the endpoint to Baseline is presented, as it is a measure of the difference from Baseline.
| ratio from Baseline | Placebo | FF/VI 100/25 µg PM | FF/VI 200/25 µg PM | Prednisolone 10 mg AM |
|---|---|---|---|---|
| Ratio From Baseline of Serum Cortisol Trough (0-24 Hours) at Day -1/1 (Baseline) and Day 42 | 1.04 ± 88.2 | 0.84 ± 88.7 | 0.73 ± 80.7 | 0.28 ± 82.3 |
A 24-hour urine sample was collected for the measurement of 24-hour urinary cortisol excretion at Day -1/1 (Baseline) and Day 42. Only those participants available at the specified time points were analyzed. Because values are on a logged scale, the ratio of the endpoint to Baseline is presented, as it is a measure of the difference from Baseline.
| ratio from Baseline | Placebo | FF/VI 100/25 µg PM | FF/VI 200/25 µg PM | Prednisolone 10 mg AM |
|---|---|---|---|---|
| Ratio From Baseline of 0-24 Hour Urinary Free Cortisol Excretion on Day -1/1 (Baseline) and Day 42 | 0.87 ± 77.923 | 1.03 ± 110.952 | 0.92 ± 96.312 | 0.40 ± 204.433 |
Plasma FF and VI Pharmacokinetic (PK) Concentration were estimates at the following time points:0 (immediately pre-dose inhaled study drug), and post-dose at 5 min, 15 min, 30 min, and 1 hr, 2 hr, 4 hr, 9 hr, 12 hr, 16 hr, 20 hr, 24 hr on Day 42. Only those participants available at the specified time points were analyzed (represented by n=X, X, X, X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the Pharmacokinetic Population.
| picograms per milliliter (pg/mL) | Placebo | FF/VI 100/25 µg PM | FF/VI 200/25 µg PM | Prednisolone 10 mg AM |
|---|---|---|---|---|
| FF, 0 hour, n=53, 54 | — | 3.57 ± NA | 10.02 ± NA | — |
| FF, 5 minutes post-dose, n=51, 54 | — | 16.65 ± 10.191 | 25.55 ± 14.438 | — |
| FF, 15 minutes post-dose, n=50, 54 | — | 16.35 ± 10.198 | 28.84 ± 14.441 | — |
| FF, 30 minutes post-dose, n=52, 52 | — | 17.12 ± 10.583 | 30.68 ± 15.461 | — |
| FF, 1 hour post-dose, n=54, 54 | — | 16.91 ± 9.637 | 30.07 ± 15.540 | — |
| FF, 2 hours post-dose, n=51, 53 | — | 15.00 ± 9.272 | 30.20 ± 18.292 | — |
| FF, 4 hours post-dose, n=54, 53 | — | 9.78 ± NA | 21.79 ± 11.597 | — |
| FF, 9 hours post-dose, n=48, 52 | — | 6.20 ± NA | 15.99 ± 11.667 | — |
| FF, 12 hours post-dose, n=51, 55 | — | 4.62 ± NA | 13.37 ± 9.670 | — |
| FF, 16 hours post-dose, n=49, 52 | — | 2.55 ± NA | 11.73 ± NA | — |
| FF, 20 hours post-dose, n=51, 51 | — | 1.74 ± NA | 9.28 ± NA | — |
| FF, 24 hours post-dose, n=48, 53 | — | 1.55 ± NA | 7.58 ± NA | — |
| VI, 0 hours, n=52, 54 | — | 2.57 ± NA | 7.95 ± NA | — |
| VI, 5 minutes post-dose, n=50, 54 | — | 85.22 ± 70.582 | 90.54 ± 88.794 | — |
| VI, 15 minutes post-dose, n=48, 55 | — | 62.94 ± 52.020 | 72.53 ± 55.271 | — |
| VI, 30 minutes post-dose, n=51, 55 | — | 33.38 ± 33.932 | 36.88 ± 33.157 | — |
| VI, 1 hour post-dose, n=52, 53 | — | 14.63 ± NA | 20.07 ± NA | — |
| VI, 2 hours post-dose, n=52, 55 | — | 7.09 ± NA | 6.06 ± NA | — |
| VI, 4 hours post-dose, n=52, 54 | — | 0.00 ± NA | 0.45 ± NA | — |
| VI, 9 hours post-dose, n=52, 55 | — | 0.00 ± NA | 0.47 ± NA | — |
| VI, 12 hours post-dose, n=52, 55 | — | 0.00 ± NA | 1.21 ± NA | — |
| VI, 16 hours post-dose, n=51, 52 | — | 0.00 ± NA | 4.76 ± NA | — |
| VI, 20 hours post-dose, n=50, 54 | — | 0.00 ± NA | 0.00 ± NA | — |
| VI, 24 hours post-dose, n=52, 55 | — | 1.19 ± NA | 0.00 ± NA | — |
Area under the plasma drug concentration-time (AUC\[0-t\]) curve from time zero (pre-dose) to the last time of quantifiable FF concentration and AUC(0-24) is the concentration time curve from zero (pre-dose) to 24 hours of quantifiable FF concentration on Day 42 was measured. AUC reflects the actual body exposure to drug over a specified period of time after administration of a dose. Samples were collected at the following times: 0 (immediately pre-dose inhaled study drug); post-dose at 5 minutes (min), 15 min, 30 min, and 1 hour (hr), 2 hr, 4 hr, 9 hr, 12 hr, 16 hr, 20 hr, and 24 hr post-dose on Day 42.
| picograms*hour per milliliter (pg*hr/mL) | Placebo | FF/VI 100/25 µg PM | FF/VI 200/25 µg PM | Prednisolone 10 mg AM |
|---|---|---|---|---|
| AUC(0-t), n=54, 55 | — | 58.842 (37.706 to 91.825) | 221.694 (152.697 to 321.868) | — |
| AUC(0-24), n=49, 53 | — | NA (NA to NA) | 324.015 (267.233 to 392.862) | — |
Cmax is defined as the maximum observed concentration on Day 42. Samples were collected at the following times: 0 (immediately pre-dose inhaled study drug); post-dose at 5 minutes (min), 15 min, 30 min, and 1 hour (hr), 2 hr, 4 hr, 9 hr, 12 hr, 16 hr, 20 hr, and 24 hr post-dose on Day 42.
| picograms per milliliter (pg/mL) | Placebo | FF/VI 100/25 µg PM | FF/VI 200/25 µg PM | Prednisolone 10 mg AM |
|---|---|---|---|---|
| Cmax for FF on Day 42 | — | 19.388 (16.796 to 22.379) | 33.017 (28.586 to 38.135) | — |
tmax is defined as the time to reach the observed maximum concentration, and tlast is defined as the time of the last observed quantifiable concentration on Day 42. Samples were collected at the following times: 0 (immediately pre-dose inhaled study drug); post-dose at 5 minutes (min), 15 min, 30 min, and 1hour (hr), 2 hr, 4 hr, 9 hr, 12 hr, 16 hr, 20 hr, and 24 hr post-dose on Day 42.
| hours | Placebo | FF/VI 100/25 µg PM | FF/VI 200/25 µg PM | Prednisolone 10 mg AM |
|---|---|---|---|---|
| tmax | — | 0.500 (0.03 to 8.97) | 0.500 (0.07 to 4.00) | — |
| tlast | — | 9.000 (0.98 to 24.00) | 20.042 (0.95 to 24.08) | — |
Area under the concentration-time (AUC\[0-t\]) curve from time zero (pre-dose) to the last time of quantifiable VI concentration on Day 42 was measured. Samples were collected at the following times: 0 (immediately pre-dose inhaled study drug); post-dose at 5 minutes (min), 15 min, 30 min, and 1 hour (hr), 2 hr, 4 hr, 9 hr, 12 hr, 16 hr, 20 hr, and 24 hr post-dose on Day 42.
| picograms*hour per milliliter (pg*hr/mL) | Placebo | FF/VI 100/25 µg PM | FF/VI 200/25 µg PM | Prednisolone 10 mg AM |
|---|---|---|---|---|
| AUC(0-t) for VI on Day 42 | — | 41.177 ± 53.9720 | 66.937 ± 142.3461 | — |
Cmax is defined as the maximum observed concentration on Day 42. Samples were collected at the following times: 0 (immediately pre-dose inhaled study drug); post-dose at 5 minutes (min), 15 min, 30 min, and 1 hour (hr), 2 hr, 4 hr, 9 hr, 12 hr, 16 hr, 20 hr, and 24 hr post-dose on Day 42.
| picograms per milliliter (pg/mL) | Placebo | FF/VI 100/25 µg PM | FF/VI 200/25 µg PM | Prednisolone 10 mg AM |
|---|---|---|---|---|
| Cmax for VI on Day 42 | — | 101.227 ± 73.8233 | 118.531 ± 86.8659 | — |
tmax is defined as the time to reach the observed maximum concentration, and tlast is defined as the time of the last observed quantifiable VI concentration on Day 42. Samples were collected at the following times: 0 (immediately pre-dose inhaled study drug); post-dose at 5 minutes (min), 15 min, 30 min, and 1hour (hr), 2 hr, 4 hr, 9 hr, 12 hr, 16 hr, 20 hr, and 24 hr post-dose on Day 42.
| hours | Placebo | FF/VI 100/25 µg PM | FF/VI 200/25 µg PM | Prednisolone 10 mg AM |
|---|---|---|---|---|
| tmax | — | 0.083 (0.00 to 2.00) | 0.083 (0.00 to 16.00) | — |
| tlast | — | 0.500 (0.03 to 2.00) | 0.950 (0.08 to 16.00) | — |
An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A serious adverse event (SAE) is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect. Medical or scientific judgment should be exercised in deciding whether reporting is appropriate in other situations. Refer to the General Adverse AE/SAE module for a complete list of AEs and SAEs.
| Participants | Placebo | FF/VI 100/25 µg PM | FF/VI 200/25 µg PM | Prednisolone 10 mg AM |
|---|---|---|---|---|
| Any AE | 16 | 23 | 21 | 5 |
| Any SAE | 0 | 0 | 0 | 0 |
Blood samples were collected for the measurement of basophils, eosinophils, lymphocytes, monocytes, and segmented neutrophils at Baseline and Day 42/EW. For all laboratory assessments, Baseline is the most recent recorded value at Screening or prior to Day -1/1. Change from Baseline was calculated as the Day 42/EW value minus the Baseline value.
| Percentage | Placebo | FF/VI 100/25 µg PM | FF/VI 200/25 µg PM | Prednisolone 10 mg AM |
|---|---|---|---|---|
| Basophils, Day 42, n=50, 47, 53, 11 | 0.05 ± 0.354 | 0.04 ± 0.356 | -0.05 ± 0.350 | -0.08 ± 0.223 |
| Basophils, EW, n=2, 2, 0, 0 | -0.10 ± 0.141 | 0.10 ± 0.141 | NA ± NA | NA ± NA |
| Eosinophils, Day 42, n=50, 47, 53, 11 | 0.57 ± 2.837 | 0.27 ± 2.073 | -0.99 ± 2.664 | -1.11 ± 1.488 |
| Eosinophils, EW, n=2, 2, 0, 0 | 0.50 ± 0.849 | -0.55 ± 2.051 | NA ± NA | NA ± NA |
| Lymphocytes, Day 42, n=50, 47, 53, 11 | 1.09 ± 6.836 | 1.54 ± 8.853 | -1.32 ± 7.844 | -2.48 ± 14.319 |
| Lymphocytes, EW, n=2, 2, 0, 0 | 2.90 ± 10.607 | 2.00 ± 2.263 | NA ± NA | NA ± NA |
| Monocytes, Day 42, n=50, 47, 53, 11 | -0.51 ± 2.074 | -0.03 ± 3.333 | 0.07 ± 2.581 | -0.70 ± 1.977 |
| Monocytes, EW, n=2, 2, 0, 0 | -1.00 ± 0.424 | -0.70 ± 3.111 | NA ± NA | NA ± NA |
| Segmented Neutrophils, Day 42, n=50, 47, 53, 11 | -1.16 ± 8.291 | -1.85 ± 10.279 | 2.30 ± 9.583 | 4.37 ± 15.667 |
| Segmented Neutrophils, EW, n=2, 2, 0, 0 | -2.30 ± 11.738 | -0.85 ± 3.465 | NA ± NA | NA ± NA |
Blood samples were collected for the measurement of eosinophils, total neutrophils, platelets, and WBC count at Baseline and Day 42/EW. For all laboratory assessments, Baseline is the most recent recorded value at Screening or prior to Day -1/1. Change from Baseline was calculated as the Day 42/EW value minus the Baseline value.
| 10^9 cells per liter (GI/L) | Placebo | FF/VI 100/25 µg PM | FF/VI 200/25 µg PM | Prednisolone 10 mg AM |
|---|---|---|---|---|
| Eosinophils, Day 42, n=50, 47, 53, 11 | 0.066 ± 0.2282 | 0.044 ± 0.1608 | -0.022 ± 0.1805 | -0.036 ± 0.0803 |
| Eosinophils, EW, n=2, 2, 0, 0 | 0.015 ± 0.0071 | -0.060 ± 0.1697 | NA ± NA | NA ± NA |
| Total Neutrophils, Day 42, n=50, 47, 53, 11 | 0.017 ± 1.3317 | 0.289 ± 1.4873 | 0.704 ± 1.2403 | 1.435 ± 2.5515 |
| Total Neutrophils, EW, n=2, 2, 0, 0 | -0.420 ± 1.7253 | -1.165 ± 0.9970 | NA ± NA | NA ± NA |
| Platelets, Day 42, n=50, 48, 51, 11 | -11.1 ± 28.72 | -8.2 ± 31.33 | -3.9 ± 25.31 | 16.1 ± 16.50 |
| Platelets, EW, n=1, 2, 0, 0 | -2.0 ± NA | -39.5 ± 28.99 | NA ± NA | NA ± NA |
| WBC Day 42, n=50, 47, 53, 11 | 0.22 ± 1.584 | 0.71 ± 1.787 | 0.96 ± 1.367 | 1.69 ± 2.418 |
| WBC EW, n=2, 2 | -0.25 ± 1.344 | -1.65 ± 0.778 | NA ± NA | NA ± NA |
Blood samples were collected for the measurement of hemoglobin at Baseline and Day 42/EW. For all laboratory assessments, Baseline is the most recent recorded value at Screening or prior to Day -1/1. Change from Baseline was calculated as the Day 42/EW value minus the Baseline value.
| Grams per liter (g/L) | Placebo | FF/VI 100/25 µg PM | FF/VI 200/25 µg PM | Prednisolone 10 mg AM |
|---|---|---|---|---|
| Day 42, n=50, 48, 53, 11 | -5.8 ± 10.28 | -6.2 ± 6.23 | -5.7 ± 6.59 | -3.5 ± 9.27 |
| EW, n=2, 2, 0, 0 | -10.5 ± 2.12 | -3.0 ± 8.49 | NA ± NA | NA ± NA |
Blood samples were collected for the measurement of hematocrit at Baseline and Day 42/EW. For all laboratory assessments, Baseline is the most recent recorded value at Screening or prior to Day -1/1. Change from Baseline was calculated as the Day 42/EW value minus the Baseline value.
| Proportion of 1 | Placebo | FF/VI 100/25 µg PM | FF/VI 200/25 µg PM | Prednisolone 10 mg AM |
|---|---|---|---|---|
| Day 42, n=50, 48, 53, 11 | -0.0123 ± 0.02957 | -0.0120 ± 0.02125 | -0.0114 ± 0.02151 | -0.0072 ± 0.02955 |
| EW, n=2, 2, 0, 0 | -0.0175 ± 0.00071 | -0.0050 ± 0.02263 | NA ± NA | NA ± NA |
Blood samples were collected for the measurement of ALT, ALP, AST, CK, and GGT at Baseline and Day 42/EW. For all laboratory assessments, Baseline is the most recent recorded value at Screening or prior to Day -1/1. Change from Baseline was calculated as the Day 42/EW value minus the Baseline value.
| International units per liter (IU/L) | Placebo | FF/VI 100/25 µg PM | FF/VI 200/25 µg PM | Prednisolone 10 mg AM |
|---|---|---|---|---|
| ALT, Day 42, n=55, 51, 55, 12 | -1.3 ± 13.05 | -2.0 ± 8.49 | -2.2 ± 10.86 | 0.8 ± 3.33 |
| ALT, EW, n=2, 2, 0, 0 | -5.0 ± 8.49 | 0.5 ± 2.12 | NA ± NA | NA ± NA |
| ALP, Day 42, n=55, 51, 55, 12 | -6.8 ± 11.06 | -2.1 ± 13.96 | -2.6 ± 8.33 | -4.9 ± 9.86 |
| ALP, EW, n=2, 2, 0, 0 | 1.5 ± 9.19 | -1.0 ± 1.41 | NA ± NA | NA ± NA |
| AST, Day 42, n=54, 50, 51, 12 | -0.1 ± 12.42 | -1.4 ± 6.82 | -0.6 ± 6.91 | -1.8 ± 5.67 |
| AST, EW, n=2, 2, 0, 0 | 0.5 ± 0.71 | 0.0 ± 1.41 | NA ± NA | NA ± NA |
| CK, Day 42, n=55, 51, 55, 12 | -42.3 ± 342.74 | -18.5 ± 289.98 | 5.5 ± 67.57 | -17.3 ± 95.02 |
| CK, EW, n=2, 2, 0, 0 | 15.0 ± 21.21 | 33.0 ± 73.54 | NA ± NA | NA ± NA |
| GGT, Day 42, n=55, 51, 55, 12 | -3.3 ± 10.65 | -2.5 ± 6.94 | 2.2 ± 17.24 | 3.1 ± 7.32 |
| GGT, EW, n=2, 2, 0, 0 | -2.5 ± 6.36 | -0.5 ± 0.71 | NA ± NA | NA ± NA |
Blood samples were collected for the measurement of albumin and total protein at Baseline and Day 42/EW. For all laboratory assessments, Baseline is the most recent recorded value at Screening or prior to Day -1/1. Change from Baseline was calculated as the Day 42/EW value minus the Baseline value.
| Grams per liter | Placebo | FF/VI 100/25 µg PM | FF/VI 200/25 µg PM | Prednisolone 10 mg AM |
|---|---|---|---|---|
| Albumin, Day 42, n=55, 51, 55, 12 | -2.7 ± 3.29 | -1.5 ± 3.02 | -1.3 ± 3.11 | -0.3 ± 2.81 |
| Albumin, EW, n=2, 2, 0, 0 | -1.5 ± 3.54 | 0.5 ± 2.12 | NA ± NA | NA ± NA |
| Total Protein, Day 42, n=55, 51, 55, 12 | -4.1 ± 5.06 | -1.9 ± 4.39 | -1.8 ± 4.65 | -0.8 ± 4.18 |
| Total Protein, EW, n=2, 2, 0, 0 | -0.5 ± 3.54 | 0.0 ± 0.00 | NA ± NA | NA ± NA |
Blood samples were collected for the measurement of direct bilirubin, indirect bilirubin, total bilirubin, and creatinine at Baseline and Day 42/EW. For all laboratory assessments, Baseline is the most recent recorded value at Screening or prior to Day -1/1. Change from Baseline was calculated as the Day 42/EW value minus the Baseline value.
| Micromoles per liter (µmol/L) | Placebo | FF/VI 100/25 µg PM | FF/VI 200/25 µg PM | Prednisolone 10 mg AM |
|---|---|---|---|---|
| Direct Bilirubin, Day 42, n=55, 51, 55, 12 | -0.6 ± 1.12 | -0.6 ± 1.02 | -0.5 ± 1.10 | 0.3 ± 0.75 |
| Direct Bilirubin, EW, n=2, 2, 0, 0 | -1.0 ± 0.00 | 0.0 ± 0.00 | NA ± NA | NA ± NA |
| Indirect Bilirubin, Day 42, n=55, 51, 55, 12 | -2.0 ± 4.89 | -2.5 ± 3.20 | -1.4 ± 4.72 | -1.0 ± 2.76 |
| Indirect Bilirubin, EW, n=2, 2, 0, 0 | -1.5 ± 2.12 | -2.0 ± 0.00 | NA ± NA | NA ± NA |
| Total Bilirubin, Day 42, n=55, 51, 55, 12 | -2.5 ± 5.66 | -3.2 ± 3.72 | -1.8 ± 5.67 | -0.8 ± 2.86 |
| Total Bilirubin, EW, n=2, 2, 0, 0 | -2.5 ± 2.12 | -2.0 ± 0.00 | NA ± NA | NA ± NA |
| Creatinine, Day 42, n=55, 51, 55, 12 | -0.41 ± 8.688 | 0.35 ± 8.088 | 0.04 ± 8.052 | 4.61 ± 9.585 |
| Creatinine, EW, n=2, 2, 0, 0 | 0.00 ± 13.435 | 0.95 ± 6.435 | NA ± NA | NA ± NA |
Blood samples were collected for the measurement of chloride, carbon dioxide (CO2) content/bicarbonate, glucose, potassium, sodium, and urea/blood urea nitrogen (BUN) at Baseline and Day 42/EW. For all laboratory assessments, Baseline is the most recent recorded value at Screening or prior to Day -1/1. Change from Baseline was calculated as the Day 42/EW value minus the Baseline value.
| Millimoles per liter (mmol/L) | Placebo | FF/VI 100/25 µg PM | FF/VI 200/25 µg PM | Prednisolone 10 mg AM |
|---|---|---|---|---|
| Chloride, Day 42, n=55, 51, 55, 12 | 1.2 ± 2.54 | 0.9 ± 2.76 | 0.7 ± 3.06 | -1.0 ± 2.41 |
| Chloride, EW, n=2, 2, 0, 0 | 2.0 ± 1.41 | -0.5 ± 0.71 | NA ± NA | NA ± NA |
| CO2 content/bicarbonate, Day 42, n=54, 50, 51, 12 | -1.0 ± 2.86 | -2.0 ± 2.98 | -1.5 ± 2.35 | -0.1 ± 3.12 |
| CO2 content/bicarbonate, EW, n=2, 2, 0, 0 | -3.5 ± 2.12 | 0.0 ± 1.41 | NA ± NA | NA ± NA |
| Glucose, Day 42, n=55, 51, 55, 12 | 0.11 ± 1.117 | 0.23 ± 1.037 | -0.03 ± 0.573 | 0.40 ± 1.397 |
| Glucose, EW, n=2, 2, 0, 0 | 1.00 ± 0.283 | 0.40 ± 0.849 | NA ± NA | NA ± NA |
| Potassium, Day 42, n=54, 50, 51, 12 | -0.10 ± 0.385 | -0.11 ± 0.405 | -0.16 ± 0.379 | 0.03 ± 0.599 |
| Potassium, EW, n=2, 2, 0, 0 | -0.20 ± 0.283 | -0.65 ± 0.071 | NA ± NA | NA ± NA |
| Sodium, Day 42, n=55, 51, 55, 12 | 0.0 ± 2.03 | -0.1 ± 1.98 | -0.1 ± 3.01 | -0.2 ± 1.85 |
| Sodium, EW, n=2, 2, 0, 0 | 1.5 ± 3.54 | -3.5 ± 0.71 | NA ± NA | NA ± NA |
| Urea/BUN, Day 42, n=55, 51, 55, 12 | -0.14 ± 1.432 | 0.48 ± 1.441 | -0.00 ± 1.236 | 0.94 ± 1.331 |
| Urea/BUN, EW, n=2, 2, 0, 0 | 1.30 ± 0.283 | -0.85 ± 0.919 | NA ± NA | NA ± NA |
SBP and DBP were measured at Baseline and at Days 14, 28, 42, and EW. Change from Baseline was calculated as the Day 42/EW value minus the Baseline value. Scheduled, unscheduled, and early withdrawal visits were used for the maximum post-Baseline assessment.
| Millimeters of mercury (mmHg) | Placebo | FF/VI 100/25 µg PM | FF/VI 200/25 µg PM | Prednisolone 10 mg AM |
|---|---|---|---|---|
| SBP, Day 14, n=58, 55, 56, 14 | -0.5 ± 11.68 | -1.9 ± 10.88 | -1.3 ± 10.53 | -1.0 ± 13.33 |
| SBP, Day 28, n=57, 55, 56, 14 | -0.9 ± 9.55 | -0.7 ± 10.70 | -2.3 ± 11.66 | -3.9 ± 13.35 |
| SBP, Day 42, n=55, 54, 56, 13 | 2.3 ± 11.96 | -0.4 ± 12.72 | -1.8 ± 11.20 | 1.5 ± 8.26 |
| SBP, maximum post-Baseline, n=58, 56, 56, 15 | 6.2 ± 11.44 | 5.0 ± 10.88 | 3.9 ± 10.80 | 4.9 ± 8.61 |
| DBP, Day 14, n=58, 55, 56, 14 | 0.0 ± 7.92 | -1.1 ± 8.26 | -0.6 ± 9.08 | 0.1 ± 8.55 |
| DBP, Day 28, n=57, 55, 56, 14 | 1.8 ± 8.38 | -0.6 ± 7.63 | 0.1 ± 9.97 | -0.4 ± 8.11 |
| DBP, Day 42, n=55, 54, 56, 13 | 1.2 ± 8.77 | -1.2 ± 9.13 | 0.3 ± 8.74 | 1.2 ± 8.69 |
| DBP, maximum post-Baseline, n=58, 56, 56, 15 | -3.3 ± 7.04 | -5.2 ± 7.76 | -5.4 ± 9.00 | -4.9 ± 7.97 |
Heart rate was measured at Baseline and at Days 14, 28, 42, and EW. Change from Baseline was calculated as the Day 42/EW value minus the Baseline value. Scheduled, unscheduled, and early withdrawal visits were used for the maximum post-Baseline assessment.
| Beats per minute | Placebo | FF/VI 100/25 µg PM | FF/VI 200/25 µg PM | Prednisolone 10 mg AM |
|---|---|---|---|---|
| Day 14, n=58, 55, 56, 14 | 1.5 ± 13.05 | 1.7 ± 10.70 | 0.0 ± 8.72 | -1.8 ± 7.92 |
| Day 28, n=57, 55, 56, 14 | 2.9 ± 13.45 | -0.9 ± 9.32 | -1.9 ± 12.05 | -2.7 ± 11.89 |
| Day 42, n=55, 54, 56, 13 | -0.1 ± 12.65 | -0.9 ± 11.43 | 0.9 ± 8.96 | -2.3 ± 9.10 |
| Maximum post-Baseline, n=58, 56, 56, 15 | 8.0 ± 12.47 | 6.0 ± 9.86 | 5.5 ± 8.64 | 2.9 ± 9.13 |
Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 0/58 (0%) | 9/58 (15.5%) |
| FF/VI 100/25 µg PM | — | 0/56 (0%) | 20/56 (35.7%) |
| FF/VI 200/25 µg PM | — | 0/56 (0%) | 13/56 (23.2%) |
| Prednisolone 10 mg AM | — | 0/15 (0%) | 5/15 (33.3%) |
| Event | Placebo | FF/VI 100/25 µg PM | FF/VI 200/25 µg PM | Prednisolone 10 mg AM |
|---|---|---|---|---|
| HeadacheNervous system disorders | 5/58 | 15/56 | 9/56 | 2/15 |
| DizzinessNervous system disorders | 0/58 | 0/56 | 0/56 | 1/15 |
| Facial palsyNervous system disorders | 0/58 | 0/56 | 0/56 | 1/15 |
| Dyspnoea exertionalRespiratory, thoracic and mediastinal disorders | 0/58 | 0/56 | 0/56 | 1/15 |
| Back painMusculoskeletal and connective tissue disorders | 0/58 | 1/56 | 2/56 | 1/15 |
| NauseaGastrointestinal disorders | 1/58 | 0/56 | 0/56 | 1/15 |
| HypotensionVascular disorders | 0/58 | 0/56 | 0/56 | 1/15 |
| Varicose veinVascular disorders | 0/58 | 0/56 | 0/56 | 1/15 |
| FatigueGeneral disorders | 0/58 | 0/56 | 0/56 | 1/15 |
| InsomniaPsychiatric disorders | 0/58 | 0/56 | 0/56 | 1/15 |
| Age, Continuous(Years) | Placebo | FF/VI 100/25 µg PM | FF/VI 200/25 µg PM | Prednisolone 10 mg AM | Total |
|---|---|---|---|---|---|
| Mean | 36.1 ± 15.42 | 34.4 ± 15.63 | 34.0 ± 13.74 | 37.5 ± 14.19 | 35.1 ± 14.82 |
| Gender(Participants) | Placebo | FF/VI 100/25 µg PM | FF/VI 200/25 µg PM | Prednisolone 10 mg AM | Total |
|---|---|---|---|---|---|
| Female | 27 | 31 | 23 | 6 | 87 |
| Male | 31 | 25 | 33 | 9 | 98 |
| Race/Ethnicity, Customized(Participants) | Placebo | FF/VI 100/25 µg PM | FF/VI 200/25 µg PM | Prednisolone 10 mg AM | Total |
|---|---|---|---|---|---|
| African American/African Heritage | 3 | 0 | 1 | 0 | 4 |
| American Indian or Alaska Native | 0 | 0 | 1 | 0 | 1 |
| Asian - Japanese Heritage | 0 | 0 | 1 | 0 | 1 |
| White - White/Caucasian/European Heritage | 55 | 56 | 53 | 15 | 179 |
Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
The record gives a start of Mar 2010, a primary completion of Sep 2010 and a completion of Sep 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2013, 2 years 11 months after primary completion. A results delay was requested in Mar 2012.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Fluticasone furoate · Vilanterol · Prednisolone